AirSculpt Q2 revenue falls more than expected

Airsculpt Technologies

10/08/2026 11:10

Overview
US body contouring provider's Q2 revenue fell 3%, missing analyst expectations
Adjusted EBITDA for Q2 declined year-over-year
Company reaffirmed full-year revenue guidance at low end, cut adjusted EBITDA outlook

Outlook
AirSculpt reaffirms 2026 revenue at lower end of $151 mln to $157 mln range
Company lowers 2026 adjusted EBITDA outlook to $12 mln to $14 mln

Result Drivers
SAME-CENTER PERFORMANCE - Co reported stable same-center sales and a 1.0% increase in same-center case volume for Q2
NEW PROCEDURE INTRODUCTION - Co introduced new services, including an exclusive partnership with AlloClae to expand treatment offering
INCREASED MARKETING INVESTMENT - Co increased brand marketing efforts during the quarter

Company press release: ID:nGNX69QhnY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$42.90 mln
$44.14 mln (3 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for AirSculpt Technologies Inc is $6.25, about 24.8% above its August 7 closing price of $5.01

Reuters Recommended Reads
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates 
Aug 7 - ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat
Aug 7 - Treace Medical Q2 revenue tops estimates on higher surgeon adoption; ups outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)